Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Boehringer Ingelheim
Harvard Business School
Medtronic
Johnson and Johnson

Last Updated: September 26, 2022

Patent: 10,058,630


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 10,058,630
Title:Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
Abstract: Methods for inhibiting stenosis, obstruction and/or calcification of a heart valve following implantation in a vessel having a wall are disclosed. In one aspect the method includes providing a bioprosthetic heart valve mounted on an elastical stent; treating the bioprosthetic heart valve with a tissue fixative; coating the stent and the bioprosthetic valve with a coating composition including one or more therapeutic agents; implanting the bioprosthetic valve into the vessel in a diseased natural valve site; eluting the coating composition from the bioprosthetic valve; and inhibiting stenosis, obstruction and/or calcification of the bioprosthetic heart valve by preventing the attachment of stem cells to the bioprosthetic heart valve, the stem cells circulating external and proximate to the bioprosthetic heart valve by activating nitric oxide production (i) in the circulating stem cells, (ii) in an endothelial cell lining covering the bioprosthetic heart valve tissue, (iii) or both.
Inventor(s): Rajamannan; Nalini M. (Chicago, IL)
Assignee: CONCIEVALVE, LLC (Minneapolis, MN)
Application Number:15/601,236
Patent Claims:see list of patent claims

Details for Patent 10,058,630

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Jubilant Hollisterstier Llc N/A positive skin test control-histamine Injection 103891 03/13/1924 See Plans and Pricing 2032-10-22
Amgen, Inc. PROLIA denosumab Injection 125320 06/01/2010 See Plans and Pricing 2032-10-22
Amgen, Inc. XGEVA denosumab Injection 125320 11/18/2010 See Plans and Pricing 2032-10-22
Amgen, Inc. REPATHA evolocumab Injection 125522 08/27/2015 See Plans and Pricing 2032-10-22
Amgen, Inc. REPATHA evolocumab Injection 125522 07/08/2016 See Plans and Pricing 2032-10-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
AstraZeneca
Medtronic
McKesson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.